Abstract: The present invention relates to biomarker polypeptides, polynucleotides, and antibodies that have utility in predicting in vitro and/or in vivo hepatotoxicity of various drugs, compounds, or other therapeutic agents (i.e., test substances). Also related are screens, kits, microarrays, and cell culture systems that employ the polypeptides, polynucleotides, and/or antibodies of the invention. The reagents and methods of the invention are useful for predicting hepatotoxic effects resulting from treatment with one or more test substances, and can be utilized before, after, or concurrently with pre-clinical, clinical, and/or post-clinical testing. In this way, the reagents and methods of the invention can be used to identify test substances or combinations of test substances that cause hepatic injury, including idiosyncratic hepatotoxicity, and thereby prevent medical complications (e.g., liver failure) resulting from such injury.

Abstract: The present invention relates to methods of screening drug candidates for toxic effects on human cells. The invention provides methods for determining idiosyncratic toxicity of test compounds.

Abstract: The present invention relates to biomarker polypeptides, polynucleotides, and antibodies that have utility in predicting in vitro and/or in vivo hepatotoxicity of various drugs, compounds, or other therapeutic agents (i.e., test substances). Also related are screens, kits, microarrays, and cell culture systems that employ the polypeptides, polynucleotides, and/or antibodies of the invention. The reagents and methods of the invention are useful for predicting hepatotoxic effects resulting from treatment with one or more test substances, and can be utilized before, after, or concurrently with pre-clinical, clinical, and/or post-clinical testing. In this way, the reagents and methods of the invention can be used to identify test substances or combinations of test substances that cause hepatic injury, including idiosyncratic hepatotoxicity, and thereby prevent medical complications (e.g., liver failure) resulting from such injury.

Abstract: The present invention relates to methods of screening drug candidates for toxic effects on human cells. The invention provides methods for determining idiosyncratic toxicity of test compounds.

Abstract: A motor vehicle seat includes a seat back which has a re-entrant rear face with a cavity closed by a sheet immobilized between two lateral uprights of the seat. Upholstery extends over the uprights and a cover covers the upholstery and is fixed into housings formed in the uprights. The sheet has lateral edges with hems into which two rods are inserted. The seat back structure includes arrangements for immobilizing the rods for fixing each of the rods into the housings and thereby to tension the sheet in the cavity, the cover being pressed into the housings by the rods.